Omeprazole is a proton pump inhibitor (PPI) that acts as an antagonist at H+/K+ ATPases and is clinically used to treat gastroesophageal reflux disease (GERD), dyspepsia, and peptic ulcer disease. Omeprazole exhibits antacid, anti-ulcerative, and anti-diabetic activities; it also inhibits the mitochondrial carnitine/acylcarnitine transporter. Omeprazole decreases blood glucose levels and Hb1Ac, improves glucose tolerance, and induces β cell neogenesis and activation.
| Cas No. | 73590-58-6 |
|---|---|
| Purity | ≥98% |
| Formula | C17H19N3O3S |
| Formula Wt. | 345.42 |
| Chemical Name | 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole |
| IUPAC Name | 6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole |
| Synonym | Antra; Gastrogard; Losec; Mepral; Omepral; Parizac' Prilosec; Zoltum |
| Melting Point | 156°C |
| Solubility | Soluble in ethanol or methanol. Slightly soluble in acetone, isopropanol, or water. |
| Appearance | White Crystalline powder |
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | O4917 MSDS PDF |
|---|---|
| Info Sheet | O4917 Info Sheet PDF |
Tonazzi A, Eberini I, Indiveri C. Molecular mechanism of inhibition of the mitochondrial carnitine/acylcarnitine transporter by omeprazole revealed by proteoliposome assay, mutagenesis and bioinformatics. PLoS One. 2013 Dec 9;8(12):e82286. PMID: 24349247.
Ward RM, Kearns GL. Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr Drugs. 2013 Apr;15(2):119-31. PMID: 23512128.
Mefford IN, Mefford JT, Burris CA. Improved diabetes control and pancreatic function in a type 2 diabetic after omeprazole administration. Case Rep Endocrinol. 2012;2012:468609. PMID: 22937295.
